全文获取类型
收费全文 | 8773篇 |
免费 | 603篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 67篇 |
儿科学 | 354篇 |
妇产科学 | 237篇 |
基础医学 | 1385篇 |
口腔科学 | 126篇 |
临床医学 | 1258篇 |
内科学 | 1594篇 |
皮肤病学 | 158篇 |
神经病学 | 953篇 |
特种医学 | 203篇 |
外科学 | 718篇 |
综合类 | 45篇 |
一般理论 | 8篇 |
预防医学 | 836篇 |
眼科学 | 152篇 |
药学 | 525篇 |
中国医学 | 9篇 |
肿瘤学 | 776篇 |
出版年
2023年 | 78篇 |
2022年 | 81篇 |
2021年 | 201篇 |
2020年 | 150篇 |
2019年 | 219篇 |
2018年 | 264篇 |
2017年 | 182篇 |
2016年 | 232篇 |
2015年 | 233篇 |
2014年 | 315篇 |
2013年 | 465篇 |
2012年 | 664篇 |
2011年 | 654篇 |
2010年 | 360篇 |
2009年 | 316篇 |
2008年 | 640篇 |
2007年 | 608篇 |
2006年 | 566篇 |
2005年 | 593篇 |
2004年 | 513篇 |
2003年 | 456篇 |
2002年 | 436篇 |
2001年 | 75篇 |
2000年 | 41篇 |
1999年 | 63篇 |
1998年 | 98篇 |
1997年 | 81篇 |
1996年 | 67篇 |
1995年 | 69篇 |
1994年 | 51篇 |
1993年 | 50篇 |
1992年 | 23篇 |
1991年 | 32篇 |
1990年 | 28篇 |
1989年 | 27篇 |
1988年 | 23篇 |
1987年 | 16篇 |
1986年 | 30篇 |
1985年 | 29篇 |
1984年 | 30篇 |
1983年 | 26篇 |
1982年 | 21篇 |
1981年 | 37篇 |
1980年 | 25篇 |
1979年 | 15篇 |
1978年 | 19篇 |
1977年 | 13篇 |
1976年 | 17篇 |
1972年 | 10篇 |
1971年 | 11篇 |
排序方式: 共有9404条查询结果,搜索用时 15 毫秒
91.
Peter Nieboer Ciska Buijs Sjoerd Rodenhuis Caroline Seynaeve Louk V A M Beex Elsken van der Wall Dick J Richel Marianne A Nooij Emile E Voest Pierre Hupperets Nanno H Mulder Winette T A van der Graaf Els M TenVergert Harm van Tinteren Elisabeth G E de Vries 《Journal of clinical oncology》2005,23(33):8296-8304
PURPOSE: Determine whether standard or high-dose chemotherapy leads to changes in fatigue, hemoglobin (Hb), mental health, muscle and joint pain, and menopausal status from pre- to post-treatment and to evaluate whether fatigue is associated with these factors in disease-free breast cancer patients. PATIENTS AND METHODS: Eight hundred eighty-five patients were randomly assigned between two chemotherapy regimens both followed by radiotherapy and tamoxifen. Fatigue was assessed using vitality scale (score < or = 46 defined as fatigue), poor mental health using mental health scale (score < or = 56 defined as poor mental health) both of Short-Form 36, muscle and joint pain with Rotterdam Symptom Checklist, and Hb levels were assessed before and 1, 2, and 3 years after chemotherapy. RESULTS: Fatigue was reported in 20% of 430 assessable patients (202 standard-dose, 228 high-dose) with at least a 3-year follow-up, without change over time or difference between treatment arms. Mean Hb levels were lower following high-dose chemotherapy. Only 5% of patients experienced fatigue and anemia. Mental health score was the strongest fatigue predictor at all assessment moments. Menopausal status had no effect on fatigue. Linear mixed effect models showed that the higher the Hb level (P = .0006) and mental health score (P < .0001), the less fatigue was experienced. Joint (P < .0001) and muscle pain (P = .0283) were associated with more fatigue. CONCLUSION: In 3 years after treatment, no significant differences in fatigue were found between standard and high-dose chemotherapy. Fatigue did not change over time. The strongest fatigue predictor was poor mental health. 相似文献
92.
Véronique Lenoir Marianne Beau Yon de Jonage-Canonico Marie-Hélène Perrin Antoine Martin Robert Scholler Bernard Kerdelhué 《Breast cancer research : BCR》2005,7(4):R470
Introduction
It has been well documented that the pineal hormone, melatonin, which plays a major role in the control of reproduction in mammals, also plays a role in the incidence and growth of breast and mammary cancer. The curative effect of melatonin on the growth of dimethylbenz [a]anthracene-induced (DMBA-induced) mammary adenocarcinoma (ADK) has been previously well documented in the female Sprague-Dawley rat. However, the preventive effect of melatonin in limiting the frequency of cancer initiation has not been well documented. 相似文献93.
94.
Recent evidence suggest that antagonism of adenosine A2A receptors represent an alternative therapeutic approach to Parkinson's disease (PD). Coactivation of A2A and the glutamate subtype 5 metabotropic receptors (mGlu5) synergistically stimulates DARPP-32 phosphorylation and c-fos expression in the striatum. This study therefore tested the effects of a joint blockade of these receptors to alleviate the motor dysfunction in a rat model of PD. 6-Hydroxydopamine infusions in the striatum produced akinetic deficits in rats trained to release a lever after a stimulus in a reaction time (RT) task. At 2 weeks after the lesion, A2A and mGlu5 receptors selective antagonists 8-(3-chlorostyryl)caffeine (CSC) and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) were administered daily for 3 weeks either as a single or joint treatment. Injections of CSC (1.25 mg/kg) and MPEP (1.5 mg/kg) separately or in combination reduced the increase of delayed responses and RTs induced by 6-OHDA lesions, while the same treatment had no effect in controls. Furthermore, coadministration of lower doses of 0.625 mg/kg CSC and 0.375 mg/kg MPEP noneffective as a single treatment promoted a full and immediate recovery of akinesia, which was found to be more efficient than the separate blockade of these receptors. These results demonstrate that the combined inactivation of A2A and mGlu5 receptor potentiate their beneficial effects supporting this pharmacological strategy as a promising anti-Parkinsonian therapy. 相似文献
95.
Sampling designs dictated by stereology have proven very useful in recent years to estimate in situ the total number of deposited particles, or of macrophages, in different lung compartments at the light microscopical level. The sampling methods are based on parallel slabs which are subsequently subsampled by disectors. The resulting number estimators are unbiased irrespective of tissue shrinkage or swelling, and they are readily applicable in other contexts (notably in neuroscience). Several variants of the design are available, however, and, although they all yield the same number estimates, their precision, and the mathematical prediction of it, vary among the different estimators and are subjected to theoretical improvement. The present paper constitutes a detailed survey of the latest advances, and it illustrates methods and formulae alike by way of a real example stemming from an earlier study on particle retention and clearance. 相似文献
96.
97.
98.
Dickens Otieno Onyango Marianne A. B. van der Sande Courtney M. Yuen Jerphason Mecha Daniel Matemo Elizabeth Oele John Kinuthia Grace JohnStewart Sylvia M. LaCourse 《Journal of the International AIDS Society》2022,25(8)
IntroductionIsoniazid preventive therapy (IPT) can reduce the risk of tuberculosis (TB) in children living with HIV (CLHIV), but data on the outcomes of the IPT cascade in CLHIV are limited.MethodsWe evaluated the IPT cascade among CLHIV aged <15 years and newly enrolled in HIV care in eight HIV clinics in western Kenya. Medical record data were abstracted from September 2015 through July 2019. We assessed the proportion of CLHIV completing TB symptom screening, IPT eligibility assessment, IPT initiation and completion. TB incidence rate was calculated stratified by IPT initiation and completion status. Risk factors for IPT non‐initiation and non‐completion were assessed using Poisson regression with generalized linear models.ResultsOverall, 856 CLHIV were newly enrolled in HIV care, of whom 98% ([95% CI 97–99]; n = 841) underwent screening for TB symptoms and IPT eligibility. Of these, 13 (2%; 95% CI 1–3) were ineligible due to active TB and 828 (98%; 95% CI 97–99) were eligible. Five hundred and fifty‐nine (68%; 95% CI 64–71) of eligible CLHIV initiated IPT; median time to IPT initiation was 3.6 months (interquartile range [IQR] 0.5–10.2). Overall, 434 (78%; 95% CI 74–81) IPT initiators completed. Attending high‐volume HIV clinics (aRR = 2.82; 95% CI 1.20–6.62) was independently associated with IPT non‐initiation. IPT non‐initiation had a trend of being higher among those enrolled in the period 2017–2019 versus 2015–2016 (aRR = 1.91; 0.98–3.73) and those who were HIV virally non‐suppressed (aRR = 1.90; 95% CI 0.98–3.71). Being enrolled in 2017–2019 versus 2015–2016 (aRR = 1.40; 1.01–1.96) was independently associated with IPT non‐completion. By 24 months after IPT screening, TB incidence was four‐fold higher among eligible CLHIV who never initiated (8.1 per 1000 person years [PY]) compared to CLHIV who completed IPT (2.1 per 1000 PY; rate ratio [RR] = 3.85; 95% CI 1.08–17.15), with a similar trend among CLHIV who initiated but did not complete IPT (8.2/1000 PY; RR = 4.39; 95% CI 0.82–23.56).ConclusionsDespite high screening for eligibility, timely IPT initiation and completion were suboptimal among eligible CLHIV in this programmatic cohort. Targeted programmatic interventions are needed to address these drop‐offs from the IPT cascade by ensuring timely IPT initiation after ruling out active TB and enhancing completion of the 6‐month course to reduce TB in CLHIV. 相似文献
99.
Jihye Kim Marianne T. Kennedy Neary Hugues Aschard Mathew M. Palakkamanil Ron Do Janey L. Wiggs Anthony P. Khawaja Louis R. Pasquale Jae H. Kang for the International Glaucoma Genetics Consortium UK Biobank Eye Vision Consortium and Modifiable Risk Factors for Glaucoma Collaboration 《Investigative ophthalmology & visual science》2022,63(5)
PurposeThe purpose of this study was to evaluate the relationship between statin use and glaucoma-related traits.MethodsIn a cross-sectional study, we included 118,153 UK Biobank participants with data on statin use and corneal-compensated IOP. In addition, we included 192,283 participants (8982 cases) with data on glaucoma status. After excluding participants with neurodegenerative diseases, 41,638 participants with macular retinal nerve fiber layer thickness (mRNFL) and 41,547 participants with macular ganglion cell inner plexiform layer thickness (mGCIPL) were available for analysis. We examined associations of statin use with IOP, mRNFL, mGCIPL, and glaucoma status utilizing multivariable-adjusted regression models. We assessed whether a glaucoma polygenic risk score (PRS) modified associations. We performed Mendelian randomization (MR) experiments to investigate associations with various glaucoma-related outcomes.ResultsStatin users had higher unadjusted mean IOP ± SD than nonusers, but in a multivariable-adjusted model, IOP did not differ by statin use (difference = 0.05 mm Hg, 95% confidence interval [CI] = −0.02 to 0.13, P = 0.17). Similarly, statin use was not associated with prevalent glaucoma (odds ratio [OR] = 1.05, 95% CI = 0.98 to 1.13). Statin use was weakly associated with thinner mRNFL (difference = −0.15 microns, 95% CI = −0.28 to −0.01, P = 0.03) but not with mGCIPL thickness (difference = −0.12 microns, 95% CI = −0.29 to 0.05, P = 0.17). No association was modified by the glaucoma PRS (Pinteraction ≥ 0.16). MR experiments showed no evidence for a causal association between the cholesterol-altering effect of statins and several glaucoma traits (inverse weighted variance P ≥ 0.14).ConclusionsWe found no evidence of a protective association between statin use and glaucoma or related traits after adjusting for key confounders. 相似文献
100.
Nina Streefkerk Marianne J. Heins Jop C. Teepen Elizabeth A. M. Feijen Dorine Bresters Eline van Dulmen‐den Broeder Margriet van der Heiden‐van der Loo Marry M. van den Heuvel‐Eibrink Flora E. van Leeuwen Jacqueline J. Loonen Helena J. H. van der Pal Ccile M. Ronckers A. Birgitta Versluys Wim J. E. Tissing Joke C. Korevaar Leontien C. M. Kremer 《Pediatric blood & cancer》2019,66(8)